Business Context and Reporting Period
This Form 6-K filing by AC Immune SA covers the month of February 2026. The Company is a biopharmaceutical firm focused on active immunotherapy programs for neurodegenerative diseases, including Alzheimer's and Parkinson's disease.
Key Financial Metrics
The filing does not provide specific numerical values for revenue, profit, cash flow, margins, or debt. However, it addresses liquidity, stating that the Company's existing capital resources are sufficient to meet projected operating requirements into Q3 2027, excluding potential milestone payments.
Material Changes and Operational Updates
- ReTain Trial Pause: Enrollment in the Phase 2b ReTain study (NCT06544616) for ACI-35.030/JNJ-2056 in preclinical Alzheimer's disease has been temporarily paused by partner Janssen Pharmaceuticals to evaluate recruitment aspects.
- Safety Status: The pause is voluntary, not related to new safety findings, and the trial's pre-specified interim immunogenicity threshold was met.
- Liquidity Impact: Management confirms the recruitment pause does not impact the Company's current liquidity position.
Outlook, Guidance, and Risks
Clinical Milestones for 2026:
- Interim 12-month results for the ABATE trial (ACI-24.060) in Alzheimer's disease (safety, immunogenicity, and Abeta PET).
- Final data from Part 1 of the VacSYn Phase 2 trial (ACI-7104.056) in early-stage Parkinson's disease.
- Start of dosing for ACI-19764 (NLRP3 inflammasome inhibitor) in a Phase 1 trial with healthy volunteers, with results expected in H2 2026.
Earnings: Q4 2025 earnings results are scheduled for release on March 12, 2026.
Investor Verification Checklist
- Verify the duration and specific reasons for the ReTain trial enrollment pause via Janssen communications.
- Confirm the exact cash balance and burn rate in the upcoming Q4 2025 earnings report to validate the Q3 2027 runway claim.
- Monitor the March 12, 2026 earnings call for any updates on the ReTain trial timeline or partnership status.
- Track the initiation of the ACI-19764 Phase 1 trial to ensure it proceeds as scheduled.